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A.12 ABSTRACTS 
of respiratory distress and improvement of roentgenographic changes) was seen in group B. There were no side effects after 
methylprednisolon treatment. 
Conclusion: the clinical efficiency of treatment with methylprednisolon may be considered established in the treatment of 
severe pneumonia. 
17. Chlamyda pneumoniae infection in COPD patients with acute exacerbation 
D. KARNAK*,S.BENGISLJN**,S.BEDERANDO.KAYACAN* 
Ankara University Medical Faculty, *Department of Chest Diseases and Tuberculosis, 
**Laboratory of Bacteriology, 06100 Cebeci-Ankaral, Turkey 
Our aim was to investigate the possible association of Chlamydia pneumoniae (Cpn) infection with acute exacerbation in 
COPD patients. For this purpose, 38 COPD patients who had acute exacerbations of respiratory conditions and 17 healthy 
smokers without respiratory disease were enrolled in the study, as study and control groups respectively. Nasopharyngeal 
swabs and paired serum samples were obtained from all subjects for antibody testing of Cpn. Sputum cultures of COPD 
patients were also performed. No pathogenic bacteria were isolated from nasopharyngeal swabs in any subject. IgM antibody 
which is a serologic evidence of recent Cpn infection was observed in 15 COPD patients (39%) and one control subject (0.5%). 
The prevalence of Cpn IgG antibodies were significantly higher in COPD patients than in control subjects (PcO.05). 
Prevalence of IgA antibodies did not show difference between two groups (P>O.O5). Microbiologic culture of the sputa 
yielded potentially pathogenic microorganisms in 23 of 38 COPD patients (60%). S. pneumoniae (4%) H. influenza (4%), 
a-hemolytic streptococcus (35%), Niesseria spp (30%), Candida spp (9%) S. aureus (4%), l? aeruginosa (4%) were isolated. 
Although a high prevalence of IgG antibodies against Cpn was detected in COPD patients, Cpn was the sole causative agent 
in only 4 patients (10%). We conclude that most patients with COPD are chronically infected with Cpn and it may either be 
the only causative agent or a co-agent in the acute exacerbation. 
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Present work evaluates 101 consecutive cases of CAP from the central Moravia hospitalized in the pulmonary department 
from 1996 to 1999. Before hospitalization 63 patients were treated with one or more antibiotics: penicillins ( 38%), macrolides 
(28%), cotrimoxazol (9%) and cephalosporins (2%). Risk factors were as follows: infiltration greater than one lobe (57 pts), 
age older than 60 (52 pts), pleural reaction (44), considerable changes in vital signs (30) polymorbidity (16), hemoptysis (lo), 
mental alteration (10) and cavitation on the chest X-ray in 8 pts. There was hypoxemia in 84 pts, hypercapnia in 13, 
leucocytosis above 20 000 in 8 and bacteremia in 6 pts. The mean length of symptom duration was 8.4 days, the mean length 
of stay in hospital was 18.9 days. Recognized pathogens were: C. pneumoniae (19) H. infuenzae (16), Enterobact. sp. (15) 
M. pneumoniae (1 l), S. pneumoniae (lo), K. pneumoniae (9). In the oral treatment fluorochinolons (23.1%), penicillins (22.2%), 
tetracyclines (21.9%) antimycotics (12.1%) cephalosporins (11.6%) and macrolides (4%) were used. Parenteral treatment was 
realized by penicillins (45.3%), cephalosporins (33.7%) and aminoglycosides (14.5%). Th ere were 9 cases of empyema, 4 cases 
of lung abscess, 6 patients were referred to ICU and 3 died. In the follow up 37 patients suffered from functional respiratory 
impairment. 
19. Moxifloxacin susceptibility program (MSP): national and regional in vitro 
susceptibility of common respiratory tract pathogens 
S. KOWALSKY, R. PRYKA, J. HARRIS, K. GRAVELLE, B. PAINTER AND THE MSP STUDY GROUP 
The Moxifloxacin Susceptibility Program (MSP) was initiated to test the susceptibilities of common respiratory tract 
pathogens against commonly prescribed antimicrobials including the new 8-methoxyfluoroquinolone, moxifloxacin. The 
comparative agents tested were trovafloxacin, levofloxacin, penicillin, cefuroxime, amoxicillin/clavulanate, azithromycin, and 
trimethoprim-sulfamethoxazole. Fresh and/or frozen clinical isolates were collected from July 1998-November 1999. 
Organisms included Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus injluenzae, Moraxella catarrhalis, and 
Klebsiella pneumoniae. The data collected included clinical source (blood/sputum) of the isolate, clinical location (community 
